The Effectiveness of Brigatinib over Crizotinib for Treating Non-Small Cell Lung Cancer
Brigatinib / Alunbrig is a cancer medication belonging to the class of anaplastic lymphoma kinase inhibitor or ALK. It has been proven to be efficient in treating non-small cell lung cancer or NSCLC that is ALK positive.
The ALK gene occurs in only 3-5 % of the patients of NSCLC. Crizotinib (also a first generation ALK inhibitor) showed a longer progression-free survival when compared to platinum based double agent chemotherapy medication.
Source: https://shorturl.at/bilG6
#BrigatinibSuccess #NSCLC #LungCancerTreatment #BrigatinibVsCrizotinib #MedicalAdvancements #cancerresearch #TargetedTherapy #PrecisionMedicine #lungcancerawareness #fightagainstcancer #TreatmentBreakthroughs #HealthcareInnovation #SurvivorStories #PersonalizedMedicine #clinicaltrials #BetterOutcomes #ImprovingSurvivalRates #InnovativeMedicine #ProgressInOncology #MedicalBreakthroughs #HopeForPatients #NSCLCTreatment
Brigatinib / Alunbrig is a cancer medication belonging to the class of anaplastic lymphoma kinase inhibitor or ALK. It has been proven to be efficient in treating non-small cell lung cancer or NSCLC that is ALK positive.
The ALK gene occurs in only 3-5 % of the patients of NSCLC. Crizotinib (also a first generation ALK inhibitor) showed a longer progression-free survival when compared to platinum based double agent chemotherapy medication.
Source: https://shorturl.at/bilG6
#BrigatinibSuccess #NSCLC #LungCancerTreatment #BrigatinibVsCrizotinib #MedicalAdvancements #cancerresearch #TargetedTherapy #PrecisionMedicine #lungcancerawareness #fightagainstcancer #TreatmentBreakthroughs #HealthcareInnovation #SurvivorStories #PersonalizedMedicine #clinicaltrials #BetterOutcomes #ImprovingSurvivalRates #InnovativeMedicine #ProgressInOncology #MedicalBreakthroughs #HopeForPatients #NSCLCTreatment
03:44 AM - Mar 06, 2024
Only people mentioned by 911GlobalMeds in this post can reply
